Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma

Clinical Trial ID NCT01582516

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Oncolytic viruses for cancer therapy.	Oncoimmunology	2013	1.36
2	The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.	PLoS One	2014	0.98
3	Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.	Front Oncol	2013	0.95
4	Glioma virus therapies between bench and bedside.	Neuro Oncol	2014	0.95
5	Sui generis: gene therapy and delivery systems for the treatment of glioblastoma.	Neuro Oncol	2015	0.94
6	Strategies in gene therapy for glioblastoma.	Cancers (Basel)	2013	0.87
7	Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.	Mol Ther Methods Clin Dev	2016	0.86
8	EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.	Drugs Future	2016	0.84
9	Gene therapy for malignant glioma.	Mol Cell Ther	2014	0.83
10	Trial Watch-Oncolytic viruses and cancer therapy.	Oncoimmunology	2015	0.83
11	Adenoviral vector-mediated gene therapy for gliomas: coming of age.	Expert Opin Biol Ther	2014	0.82
12	Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.	Ther Deliv	2015	0.78
13	Recent advances and future of immunotherapy for glioblastoma.	Expert Opin Biol Ther	2016	0.77
14	A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells.	Stem Cells Int	2016	0.75